The Technical Analyst
Sierra Oncology Inc [SRRA]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology
Stock Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-1.49% $18.56
Last updated: 21 Jan 2022 @ 11:25 am
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 279.42 mill |
| EPS: | -7.16 |
| P/E: | 0.000 |
| Earnings Date: | Mar 09, 2022 |
| SharesOutstanding: | 15.06 mill |
| Avg Daily Volume: | 0.0596 mill |
| RATING 2022-01-20 |
|---|
| B |
| Neutral |
| RATING DETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/20 | 3/20 | 4/20 | 1/21 | 2/21 | 3/21 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$28.49 (53.50%) $9.93 |
| Date: 2022-01-21 |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2021-11-24 | Collard Craig A | Buy | 7 899 | Common Stock |
| 2021-11-23 | Collard Craig A | Buy | 5 601 | Common Stock |
| 2021-06-08 | Sinclair Andrew | Buy | 6 000 | Stock Option (Right To Buy) |
| 2021-06-08 | Allen Andrew R | Buy | 6 000 | Stock Option (Right To Buy) |
| 2021-06-08 | Ashiya Mona | Buy | 6 000 | Stock Option (Right To Buy) |
| INSIDER POWER |
|---|
| 91.46 |
| Last 100 transactions |
| Buy: 16 891 499 | Sell: 112 473 |
Forecast:
13:03 - $18.17
Live Trading Signals (every 1 min)
Forecast 1: 11:33 - $18.62
Forecast 2: 12:23 - $18.21
Forecast 3: 13:03 - $18.17
SCORE
-1.50
Sell
-1.50
Sell
Score Algorithm Version: 1.0b
Last version updated: Wed 15th Dec 2021
Last version updated: Wed 15th Dec 2021
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $18.56 (-1.49% ) |
| Volume | 0.0336 mill |
| Avg. Vol. | 0.0596 mill |
| % of Avg. Vol | 56.30 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For SRRA
14 Signals | Accuracy: 14.29% | Accuracy Buy: 0.00% | Accuracy Sell: 28.57%
Avg return buy: -0.78 % | Avg return sell: -0.72 %
| Date | Signal | @ | Closed | % | Jan 20 - 21:42 | sell | $18.84 | N/A | Active |
|---|---|---|---|---|
| Jan 20 - 21:25 | buy | $19.00 | $18.84 @ Jan 20 - 21:42 | -0.84% |
| Jan 20 - 21:17 | sell | $18.86 | $19.00 @ Jan 20 - 21:25 | 0.74% |
| Jan 20 - 15:02 | buy | $18.86 | $18.86 @ Jan 20 - 21:17 | 0.00% |
| Jan 19 - 21:21 | sell | $18.30 | $18.86 @ Jan 20 - 15:02 | 3.06% |
| Jan 19 - 21:06 | buy | $18.30 | $18.30 @ Jan 19 - 21:21 | 0.00% |
| Jan 19 - 20:58 | sell | $18.07 | $18.30 @ Jan 19 - 21:06 | 1.27% |
| Jan 19 - 20:42 | buy | $18.29 | $18.07 @ Jan 19 - 20:58 | -1.20% |
| Jan 19 - 20:19 | sell | $18.12 | $18.29 @ Jan 19 - 20:42 | 0.94% |
| Jan 19 - 19:48 | buy | $18.64 | $18.12 @ Jan 19 - 20:19 | -2.79% |
SRRA
Sierra Oncology, Inc. is late stage drug development company. The Company is focused on advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Momelotinib, the Company’s lead drug candidate, is a potent, selective and orally-bioavailable janus kinase one (JAK1), janus kinase two (JAK2) and activin a receptor type one (ACVR1) inhibitor with a differentiated therapeutic profile in myelofibrosis. The Company is also developing a portfolio of deoxyribonucleic acid (DNA) damage response (DDR) assets, consisting of SRA737 and SRA141. SRA737 is a potent, selective, orally bioavailable small molecule inhibitor of checkpoint kinase 1 (Chk1), a key regulator of cell cycle progression and the DDR network. SRA141 is a potent, selective, orally bioavailable small molecule inhibitor of Cell division cycle 7 kinase (Cdc7).
Latest Press Releases
2022-01-19 12:00:00 - Press Release
Momelotinib Review Article Published In Journal Of Hematology & Oncology Highlights Importance Of Anemia Benefit For Myelofibrosis Patients
San mateo, calif.--(business wire)--sierra oncology, inc. (nasdaq: srra), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced the publication of a review article in the journal of hematology & oncology that outlines the potential ability of momelotinib—a novel jak1, jak2 and acvr1 / alk2 inhibitor—to address the critical unmet need of anemia for myelofibrosis patients. srdan verstovsek, md, phd, chief, section for myeloprolifer
2022-01-18 07:00:00 - Press Release
Sierra Oncology Updates Topline Data Timing For Pivotal Phase 3 Trial Of Momelotinib In Myelofibrosis
San mateo, calif.--(business wire)--sierra oncology, inc. (nasdaq: srra), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, today announced it has shortened the timeline to the topline data readout of the momentum pivotal phase 3 trial of momelotinib in patients with myelofibrosis. the company now expects to announce topline data by the end of january 2022. assuming positive results, the company intends to file a new drug application (nda) with
2022-01-07 16:05:00 - Press Release
Sierra Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
San mateo, calif.--(business wire)--sierra oncology, inc. (srra), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to nine new employees as approved by the compensation committee of the company's board of directors, under sierra oncology's 2018 equity inducement plan. the 2018 equity inducement plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individuals entering into
2021-12-13 18:34:00 - Press Release
Sierra Oncology Reports Baseline Ferritin Differentially Predicts Week 24 Transfusion Independence Response In Myelofibrosis Patients
Atlanta--(business wire)--sierra oncology, inc. (nasdaq: srra), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced data from new retrospective analyses of the phase 3 simplify studies demonstrate baseline ferritin differentially predicts week 24 transfusion independence response for momelotinib and ruxolitinib in patients with myelofibrosis. the data were presented at the 63rd american society of hematology (ash) an
2021-12-06 07:00:00 - Press Release
Sierra Oncology Announces Investor Event To Review Momentum Trial Design And Available Phase 3 Momelotinib Data In Myelofibrosis
San mateo, calif.--(business wire)--sierra oncology, inc. (nasdaq: srra), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, today announced it will host an analyst and investor event on thursday, december 16, 2021, at 12:00 pm et. the event will feature a presentation by prithviraj bose, md, department of leukemia, md anderson cancer center, on the importance of treating anemia in myelofibrosis patients. dr. bose will also review
Latest News
2021-09-03 16:05:00 - Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
SAN MATEO, Calif.--(BUSINESS WIRE)--Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted stock options to five new employees as approved by the Compensation Committee of the Company's Board of Directors, under Sierra Oncology's 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual
2021-08-06 08:06:55 - Benzinga
Sierra Oncology Bets $216M On AstraZeneca's BET Inhibitor For Myelofibrosis
Sierra Oncology Inc (NASDAQ: SRRA) has acquired an exclusive global license from AstraZeneca Plc (NASDAQ: AZN) for AZD5153, a potent, and selective BRD4 BET inhibitor with a novel bivalent binding mode. Sierra plans to initiate a Phase 2 study evaluating momelotinib in combination with AZD5153 in myelofibrosis patients in 1H of 2022.
2021-06-21 07:00:00 - PRNewsWire
Sierra Oncology Announces Completion of Enrollment for MOMENTUM Phase 3 Trial
—Topline data anticipated in Q1 2022 with NDA filing to follow in H2 2022— SAN MATEO, Calif., June 21, 2021 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced the completion of enrollment for its pivotal Phase 3 MOMENTUM clinical trial evaluating the novel JAK1, JAK2 and ACVR1 / ALK2 inhibitor momelotinib in myelofibrosis patients who are symptomatic and anemic.
2021-01-27 16:09:05 - Seeking Alpha
Sierra Oncology: Time To Enter For The Big Pie
For all practical purposes, Sierra Oncology today is a single product company, solely focused on its most advanced product, momelotinib, which is targeted at Myelofibrosis. There will likely be easier times ahead, which will allow investors to take calls on the company's stock with far greater confidence, possibly after SRRA's ongoing Phase 3 trial results.